Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer

ABSTRACT: Pancreatic cancer is a heterogenous disease and consists of distinct subtypes. Here, we searched for candidate suppressor genes of the basal-like/squamous subtype, a more aggressive molecular subtype of pancreatic ductal adenocarcinoma (PDAC). Through an integrated transcriptome analysis, we identified the ELAPOR1/KIAA1324, as being downregulated in the basal-like/squamous PDAC using a discovery and validation approach. ELAPOR1 downregulation associated with decreased patient survival. The goal of this study was aimed to identify ELAPOR1 induced molecular signatures in PDAC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE243879 | GEO | 2024/01/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

LMO3 is a suppressor of the basal-like/squamous PDAC subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism

Project description:Pancreatic cancer is a heterogenous disease and consists of distinct subtypes. Here, we searched for candidate suppressor genes of the basal-like/squamous subtype, a more aggressive molecular subtype of pancreatic ductal adenocarcinoma (PDAC). Through an integrated transcriptome analysis, we identified the LMO3, as being downregulated in the basal-like/squamous PDAC using a discovery and validation approach. LMO3 downregulation associated with decreased patient survival. The goal of this study was aimed to identify LMO3 induced molecular signatures in PDAC.

2024-02-08 | GSE246660 | GEO

SERPINB3 induces the aggressive basal-like/squamous subtype and promotes invasion and metastasis in pancreatic cancer III

Project description:Pancreatic cancer is a heterogenous disease and consists of distinct subtypes. Here, we searched for candidate driver genes of the basal-like/squamous subtype, a more aggressive molecular subtype of pancreatic ductal adenocarcinoma (PDAC). Through an integrated transcriptome analysis, we identified the serine/cysteine protease inhibitor, SERPINB3 (squamous cell carcinoma antigen 1, SCCA1), as being upregulated in the basal-like/squamous PDAC using a discovery and validation approach. SERPINB3 upregulation associated with decreased patient survival and a transcriptome profile indicative of the basal-like/squamous subtype. The goal of this study was aimed to identify SERPINB3 induced molecular signatures in PDAC.

2023-10-12 | GSE224564 | GEO

SERPINB3 induces the aggressive basal-like/squamous subtype and promotes invasion and metastasis in pancreatic cancer II

2023-10-12 | GSE223908 | GEO

SERPINB3 induces the aggressive basal-like/squamous subtype and promotes invasion and metastasis in pancreatic cancer I

2023-10-12 | GSE223536 | GEO

<scp>ELAPOR1</scp> induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal-like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to the development of the aggressive basal-like/squamous subtype. Using our integrated approach, we identified endosome-lysosome associated apoptosis and autophagy regulator 1 (ELAPOR1/KIAA1324) as a candidate tumor suppressor in both our NCI-UMD-German cohort and additional validation cohorts. Diminished ELAPOR1 expression was linked to high histological grade, advanced disease stage, the basal-like/squamous subtype, and reduced patient survival in PDAC. In vitro experiments demonstrated that ELAPOR1 transgene expression not only inhibited the migration and invasion of PDAC cells but also induced gene expression characteristics associated with the classical/progenitor subtype. Metabolome analysis of patient tumors and PDAC cells revealed a metabolic program associated with both upregulated ELAPOR1 and the classical/progenitor subtype, encompassing upregulated lipogenesis and downregulated amino acid metabolism. 1-Methylnicotinamide, a known oncometabolite derived from S-adenosylmethionine, was inversely associated with ELAPOR1 expression and promoted migration and invasion of PDAC cells in vitro. Taken together, our data suggest that enhanced ELAPOR1 expression promotes transcriptome and metabolome characteristics that are indicative of the classical/progenitor subtype, whereas its reduction associates with basal-like/squamous tumors with increased disease aggressiveness in PDAC patients. These findings position ELAPOR1 as a promising candidate for diagnostic and therapeutic targeting in PDAC.

2024-04-02 | MTBLS9418 | MetaboLights

ADRA2A is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer

Project description:Pancreatic cancer is a heterogeneous disease and consists of distinct subtypes. Here, we investigated candidate suppressor genes of the basal-like/squamous subtype, a more aggressive molecular subtype of pancreatic ductal adenocarcinoma (PDAC). Through an integrated transcriptome analysis, we identified the ADRA2A, as being downregulated in the basal-like/squamous PDAC using a discovery and validation approach. ADRA2A downregulation is associated with decreased patient survival. The goal of this study was to identify ADRA2A-induced molecular signatures in PDAC.

2024-06-28 | GSE259390 | GEO

Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer

Project description:Recently, genome-wide molecular analyses have identified an altered axon guidance SLIT-ROBO signaling pathway in Pancreatic ductal adenocarcinoma (PDAC). To examine whether ROBO3 signaling is involved in the transcriptional determination of basal-like PDAC-subtype specification and functions, we performed RNA-seq analysis following ROBO3 silencing in the basal-like cell line PANC1.

2022-07-31 | E-MTAB-11476 | biostudies-arrayexpress

Glucocorticoid Receptor Suppresses GATA6-Mediated RNA Polymerase II Pause Release to Modulate Classical Subtype Identity in Pancreatic Cancer

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively. This study aims to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity. We integrated primary tumor single-cell RNA-seq, patient-derived xenograft RNA-seq, and multispectral imaging to identify MTF-dependent, subtype-specific markers. We created subtype-specific fluorescent reporter systems and conducted drug screenings to find actionable targets. We analyzed genome-wide occupancy (ChIP-seq) for epigenetic status (H3K27ac), MTFs (GATA6, ΔNp63), RNA polymerase II (Pol II), nascent RNA capture sequencing (PRO-seq), and H3K4me3-anchored chromatin topology (HiChIP). Additionally, we used nuclease-dead Cas9 (dCas9) to manipulate transcriptional regulatory mechanisms. Our approach identified glucocorticoid receptor (GR) agonists as agents that suppress the classical transcriptional program by modulating GATA6 activity. GATA6 regulates classical-specific transcription through promoter-proximal pause (PPP) release. Depletion of GATA6 increased Pol II occupancy at GATA6-bound enhancers and transcriptional start sites, stabilizing enhancer-promoter interactions. Artificially inducing pausing at GATA6-bound enhancers with dCas9 abrogated target gene expression and induced pausing at both the enhancer and target gene promoter. Conversely, ΔNp63 in basal PDAC promotes Pol II recruitment and stabilizes enhancer-promoter interactions. This study provides new insights into the transcriptional control of PDAC subtypes and suggests potential therapeutic strategies, highlighting the role of glucocorticoids in PDAC chemotherapy.

2025-01-07 | GSE271732 | GEO

Glucocorticoid Receptor Suppresses GATA6-Mediated RNA Polymerase II Pause Release to Modulate Classical Subtype Identity in Pancreatic Cancer

2025-01-07 | GSE271731 | GEO

Glucocorticoid Receptor Suppresses GATA6-Mediated RNA Polymerase II Pause Release to Modulate Classical Subtype Identity in Pancreatic Cancer

2025-01-07 | GSE272796 | GEO